Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Mills

Showing results (1011-1020 of 1,298) with videos related to

Pageof 130
Sort By:
The Journal of Clinical Investigation|February 24, 2015
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanomaLawrence N Kwong, Genevieve M Boland, Dennie T Frederick, et al.
Cancer Research|May 18, 2017
Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of CancerHengyu Lu, Nicole Villafane, Turgut Dogruluk, et al.
BMC Cancer|July 18, 2018
AKT isoform-specific expression and activation across cancer lineagesJue Wang, Wei Zhao, Huifang Guo, et al.
The Journal of Experimental Medicine|November 26, 2021
WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathwayEnsong Guo, Rourou Xiao, Yifan Wu, et al.
Nature Communications|August 9, 2025
Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patientsTravis W Moore, Elias Spiliotopoulos, Rowan L Callahan, et al.
Brain : a Journal of Neurology|September 9, 2016
Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypesEmma S Reid, Apostolos Papandreou, Suzanne Drury, et al.
Molecular Cancer Therapeutics|February 4, 2010
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line setEun Sung Park, Rosalia Rabinovsky, Mark Carey, et al.
Theranostics|July 30, 2020
RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBCSeong-Jin Kim, Jin-Sung Ju, Myoung-Hee Kang, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|November 5, 2025
ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancerShen-Nan Shi, Qiuyang Xu, Zhiqi Liao, et al.
Annals of Surgical Oncology|September 23, 2017
Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free SurvivalCallisia N Clarke, Michael S Lee, Wei Wei, et al.
Pageof 130

Showing results (1011-1020 of 1,298) with videos related to

Sort By:
Pageof 130
The Journal of Clinical Investigation|February 24, 2015
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanomaLawrence N Kwong, Genevieve M Boland, Dennie T Frederick, et al.
Cancer Research|May 18, 2017
Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of CancerHengyu Lu, Nicole Villafane, Turgut Dogruluk, et al.
BMC Cancer|July 18, 2018
AKT isoform-specific expression and activation across cancer lineagesJue Wang, Wei Zhao, Huifang Guo, et al.
The Journal of Experimental Medicine|November 26, 2021
WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathwayEnsong Guo, Rourou Xiao, Yifan Wu, et al.
Nature Communications|August 9, 2025
Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patientsTravis W Moore, Elias Spiliotopoulos, Rowan L Callahan, et al.
Brain : a Journal of Neurology|September 9, 2016
Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypesEmma S Reid, Apostolos Papandreou, Suzanne Drury, et al.
Molecular Cancer Therapeutics|February 4, 2010
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line setEun Sung Park, Rosalia Rabinovsky, Mark Carey, et al.
Theranostics|July 30, 2020
RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBCSeong-Jin Kim, Jin-Sung Ju, Myoung-Hee Kang, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|November 5, 2025
ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancerShen-Nan Shi, Qiuyang Xu, Zhiqi Liao, et al.
Annals of Surgical Oncology|September 23, 2017
Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free SurvivalCallisia N Clarke, Michael S Lee, Wei Wei, et al.
Pageof 130